ATR serine/threonine kinase inhibitor

oral agent in Ph. II for cancer

from mTOR-program derived hit + opt.

Clinical Cancer Research

AstraZeneca, Cambridge, UK

Chemical structure of Ceralasertib (AZD6738)

The AstraZeneca ATR serine/threonine kinase inhibitor, ceralasertib (AZD6738), is a potent (1 nM biochemical IC50), orally bioavailable, ATP-competitive inhibitor, and is one of the most clinically advanced sulfoximines with ~32 registered clinical…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: